Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers

@article{Hedner2005YohimbinePA,
  title={Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers},
  author={Thomas Hedner and Boo Edgar and Lars Edvinsson and Jan Hedner and Bengt Persson and Anders Pettersson},
  journal={European Journal of Clinical Pharmacology},
  year={2005},
  volume={43},
  pages={651-656}
}
SummaryThe pharmacokinetics of yohimbine and its effects on sympathoadrenal function were studied in 13 young, healthy, male volunteers after an IV bolus dose of 0.25 or 0.5 mg · kg−1.Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and IS min, and the elimination half life ranged between 0.25 and 2.5 h. The volume of distribution (Vss) was 741, (range 26 to 1271). Only 0.5 to 1 % of unchanged yohimbine was found in the urine, indicating that the major… 

The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse.

The increased plasma concentrations in the presence of detomidine has the potential to cause untoward effects and therefore further studies to assess the physiologic effects of this combination of drugs are warranted.

The antagonistic effects of atipamezole and yohimbine on stress-related neurohormonal and metabolic responses induced by medetomidine in dogs.

  • T. AmbriskoY. Hikasa
  • Biology, Medicine
    Canadian journal of veterinary research = Revue canadienne de recherche veterinaire
  • 2003
When medetomidine-induced sedation is antagonized in dogs, it is recommended to use atipamezole IM, from 2- to 6-fold the dose of medetamidine, unless otherwise indicated.

Effects of three antagonists on selected pharmacodynamic effects of sublingually administered detomidine in the horse.

At the doses administered in this study, the alpha2 -adrenergic antagonistic effects of tolazoline, yohimbine and atipamezole on cardiac and behavioral effects elicited by SL administration of detomidine are transient and incomplete.

Yohimbine Attenuates Baroreflex-Mediated Bradycardia in Humans

Yohimbine selectively attenuates baroreflex heart rate control in normotensive young men possibly through parasympathetic mechanisms as well as endogenous &agr;-2 adrenergic tone mediates a similar response.

Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial

Yohimbine is proposed to be a suitable probe drug to predict CYP2D6 activity and the microdose can be used in combination with microdosed midazolam to simultaneously evaluate CYP3A activity without any interaction between the probe drugs and because the microdoses exert no pharmacological effects.

Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition

Cardiovascular reactivity to mental stress is not related to pharmacologically manipulated tonic central sympathetic nervous system activity by alpha2-adrenergic agonists and antagonists, and these results do not support the assumption that cardiovascular reactivity is an index of toniccentral sympathetic nervous System activity.

Effect of Adrenergic Drugs on the Lipopolysaccharide-Induced Oxidative Stress and Liver Damage in the Rat

  • O. M. Salam
  • Biology, Medicine
    SOJ Diabetes and Endocrinology Care
  • 2021
A benefit from blockade of beta-adrenoceptors in protecting the liver during mild systemic inflammation in part by decreasing oxidative stress is indicated.

Yohimbine-Induced Amygdala Activation in Pathological Gamblers: A Pilot Study

The present data support the hypothesis of brain sensitization to pharmacologically-induced stress in PG, and reveal significant left amygdala activation in response to yohimbine across all PG subjects.

The impact of Yohimbine-induced arousal on facets of behavioural impulsivity

These results support the notion that impulsive behaviour is dependent upon state physiological arousal; however, distinct facets of impulsivity are differentially affected by physiological changes.

References

SHOWING 1-10 OF 35 REFERENCES

The pharmacokinetics of yohimbine in man

The results suggest that yohimbine is eliminated primarily through metabolism since the rapid plasma clearance of yohimine was not the result of renal elimination or sequestration by RBC.

The pharmacokinetic properties of yohimbine in the conscious rat

The rapid entry of yohimbine into the brain, the slow rate of elimination of yOHimbine from serum and brain and the linear relationship of brain yohimine concentration as a function of dose should be taken into consideration whenever yohIMine is to be used as a probe of α2-adrenoceptor function in vivo.

Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.

Oral yohimbine in human autonomic failure

Yohimbine may be useful in the treatment of orthostatic hypotension associated with autonomic failure and enhances discharge of the patient's own sympathetic system, unique among current modes of therapy for this disorder.

Ketanserin in essential hypertension: Effects during rest and exercise

It is concluded that ketanserin lowers BP in essential hypertension without interference with cardiovascular reflexes during standing or exercise, and that the compound may offer an alternative approach in the treatment of hypertension.

Autonomic and psychic effects of yohimbine hydrochloride

Central nervous system depressants, amobarbital and Ro 5–0690, reduced the degree of response to yohimbine, whilst the CNS stimulants imipramine and epinephrine potentiated the yohimine effect.

Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine

Yohimbine, a selective α2‐adrenoceptor antagonist, had a favorable effect in orthostatic hypotension and induced a significant increase in blood pressure and a pharmacodynamic and pharmacokinetic interaction between yohimbines and clomipramine or demethylclomipramsine was discussed.

Effects of yohimbine in obsessive compulsive disorder

The data suggest it is unlikely that abnormal noradrenergic function plays a primary role in the pathogenesis of OCD, and that OCD patients, like previous reports of depressed and panic disorders patients, had an increased cortisol response to yohimbine.

α2‐Antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers

The use of highly selective α2‐antagonists will allow investigations intoα2‐adrenoceptors, which may represent a novel locus for pharmacological intervention in lipid‐mobilization strategies.